Introduction
Alzheimer’s disease (AD) is characterized by progressive cognitive decline, with memory loss being one of the earliest clinical symptoms. The neuropathological hallmark of AD is the presence of diffuse and neuritic plaques composed of amyloid-β (Aβ) peptides formed by proteolytic cleavage of the amyloid precursor protein (APP) by β- and γ-secretases [[
1]]. Increased production or reduced clearance of Aβ is considered a prerequisite for the neuropathological and clinical manifestation of AD [[
2],[
3]]. However, the initial memory impairments in AD patients are not temporally correlated with the formation of Aβ plaques in brain areas that are important for memory processing, such as the hippocampus, and the mechanisms underlying memory loss in AD remain unclear [[
4]].
The hippocampus plays a central role in early memory loss in AD patients [[
5]]. The earliest neuropathological changes in AD are consistently observed in the medial temporal lobe (entorhinal cortex and hippocampus) [[
6]], and hippocampal volume loss is the best established diagnostic marker for AD and highly predictive of disease progression [[
7]]. Early deficits in hippocampal memory performance and synaptic plasticity have been established in various animal models of AD, before neuropathological changes are observed and in the absence of neurodegeneration [[
8],[
9]]. Hippocampal synaptic dysfunction thus most likely underlies initial memory deficits in AD and may trigger further disease progression [[
10]–[
13]].
To identify mechanisms that contribute to hippocampal synaptic dysfunction in AD we performed an unbiased synapse-oriented proteomics screen in APPswe/PS1dE9 (APP/PS1) transgenic mice [[
14]]. APP/PS1 have increased Aβ production resulting from the introduction of two human disease-related mutations, one in
APP and one in presenilin 1 (
PSEN1). Although transgenic mouse models that overproduce mutant APP generally fail to reproduce the full spectrum of pathological and clinical symptoms observed in AD, they are useful for studying early pre-pathological memory and plasticity impairments due to increased β-amyloidosis [[
9],[
15]–[
19]]. Here we report that early memory and plasticity deficits in 3 months old APP/PS1 mice coincide with an increase in hippocampal extracellular matrix (ECM) levels and are reversed by local enzymatic digestion of the ECM. Our findings thus highlight the ECM as a novel potential target in the treatment of early cognitive decline in AD.
Discussion
The earliest clinical manifestation of AD is memory loss due to hippocampal synaptic dysfunction [[
13]]. Employing an unbiased proteomics screen we demonstrate an early and significant upregulation in hippocampal synaptosome preparations of several ECM proteins. This upregulation coincides with an increase in synaptic Aβ levels, but precedes Aβ plaque pathology. Importantly, early memory and LTP deficits in APP/PS1 mice could be reversed by acute and local inactivation of the ECM using ChABC. Previous studies showed an upregulation of the ECM in late stage AD patients as well as in 10 months old APP/PS1 mice [[
49]], and suggest a neuroprotective role for ECM structures in human AD brains [[
50]]. Our observations suggest that the increase in ECM levels occurs earlier, and in addition to being protective also contributes to early memory and plasticity impairments in AD. Our focus on synaptosomal preparations may have contributed to the detection of localized ECM alterations that remained undetected in previous studies.
As a measure of hippocampal memory deficits we used contextual fear memory acquisition. We observed that 3–4 months old APP/PS1 mice are impaired in this task, but that spatial reference memory, as measured in a Morris water maze, is still intact. Impaired contextual fear memory at 3 months of age was previously reported for APP mice [[
16]], although other studies suggest the absence of fear memory deficits until 6 months of age [[
51],[
52]]. These discrepancies are most likely due to differences in genetic background or in the training protocols used. The absence of a spatial reference memory deficit is in line with previous studies showing that water maze learning in APP/PS1 mice is only affected from 6–8 months of age [[
34],[
35]]. Although contextual fear conditioning and maze learning both critically depend on the processing of contextual information in the hippocampus, fear memory acquisition requires a single pairing of context and shock, whereas maze learning involves repeated exposure of the animal to the context. One explanation might be that hippocampal plasticity deficits in 3–4 months old APP/PS1 mice are masked by repeated stimulation, whereas they are revealed in situations where animals need to process a single stimulus and respond adequately immediately. Alternatively, fear learning might use different hippocampal circuitry and thus be differently organized and differentially affected in APP/PS1 mice. The fear memory deficit at 3 months of age was paralleled by a strong reduction in LTP induction. This is in line again with previous LTP measurements in APP/PS1 mice [[
47],[
48]], although the extent of the LTP deficit differs per study and probably depends on the stimulation and recording conditions used. We conclude that both behavioral plasticity (fear conditioning) and physiological plasticity (LTP) are early affected in APP/PS1 mice, and that local degradation of the ECM with ChABC reverses these early deficits.
Interestingly, at 12 months of age, wildtype mice also show an increase in ECM protein levels, and no differences are observed anymore between APP/PS1 and wildtype animals. This is in accordance with our recent findings that an age-dependent increase in hippocampal ECM levels correlates with normal age-dependent cognitive decline [[
37]]. Apparently, age-dependent hippocampal ECM accumulation is accelerated in APP/PS1 mice and contributes to early memory impairments, whereas later in the disease, other pathological mechanisms are responsible for further cognitive decline.
ECM in the brain is organized in different specialized structures. PNNs are mesh-like structures that surround the cell body and proximal dendrites of many neurons, whereas perisynaptic matrix is associated with individual synapses [[
53]]. Our finding that ECM proteins are upregulated in synaptosomal preparations from APP/PS1 mice suggests an increase in perisynaptic ECM levels. Neuronal synthesis and synaptic release of ECM proteins might contribute to this upregulation [[
49],[
54]]. The importance of perisynaptic ECM structures was demonstrated in hippocampal slice preparations where local treatment with ChABC enhanced spine motility without affecting PNNs [[
55]]. It was demonstrated that perisynaptic matrix forms a physical barrier that restrict the lateral diffusion of AMPA receptors at postsynaptic sites [[
56],[
57]], and that activity-dependent local degradation of perisynaptic matrix results in an integrin receptor-dependent increase in LTP [[
58],[
59]]. Perisynaptic ECM could thus potentially contribute to the plasticity deficits observed in APP/PS1 mice. However, we also showed an increase in ECM-containing PNNs, in particular around PV interneurons. The number of PV neurons in CA1 with WFA-positive PNNs significantly increased from ~60% in wildtype mice to ~80% in APP/PS1 mice, whereas the total number of PV neurons remained unchanged. These findings suggest that PNNs at least also contribute to the observed memory impairments.
Previous studies reported that 50-60% of the PV neurons contain PNNs [[
60]]. PNNs regulate diverse aspects of brain plasticity [[
61]]. A developmental increase in cortical PNNs for instance corresponds with the ending of critical periods and the maturation of cortical circuits [[
62]], and ChABC treatment can reactivate ocular dominance plasticity in the adult visual cortex [[
41],[
42]]. In that respect it is interesting to note that APP/PS1 mice lack ocular dominance plasticity in the visual cortex at one month of age [[
63]]. PNNs also regulate adult learning and memory. In the amygdala, PNNs protect fear memories from erasure, and local injection of ChABC into the amygdala enhances extinction of fear [[
44]]. Genetic or ChABC-mediated degradation of PNNs in the perirhinal cortex enhances recognition memory [[
45]], and injection of the ECM-degrading enzyme hyaluronidase into the auditory cortex of Mongolian gerbils promotes context-dependent auditory reversal learning [[
64]]. A recent study showed for the first time that PV interneuron plasticity is also critically involved in the regulation of hippocampal learning and memory [[
65]]. Learning was associated with a transient decrease in PV neuron activity, whereas a relatively high PV neuron activity was observed when memory was consolidated. ChABC treatment was able to induce a low activity state in PV neurons and enhanced learning, indicating the importance of PNNs in regulating hippocampal PV neuron activity. Interestingly, in AD patients, abnormal hippocampal network activity resulting from dysfunctional inhibitory interneurons is a well-established early pathological symptom [[
66]].
At this moment we cannot distinguish the contribution of perisynaptic ECM from that of PNNs to the observed memory and plasticity deficits. Neither WFA staining nor ChABC treatment are specific enough to differentiate between these two possibilities, and likely they are both involved. In addition, it cannot be excluded that APP itself contributes to plasticity-restoring effects of ChABC. Shioi et al. [[
67]] reported the existence of a chondroitin sulfate proteoglycan form of APP, which, if existent in APP/PS1 transgenic mice, could contribute to our observations. Future experiments should address these different possibilities using more sophisticated tools for ECM protein detection and intervention.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.